One-Year Outcomes Data from the OptiMesh SCOUT Published

One-Year outcomes data from the OptiMesh SCOUT Spineology® Clinical Outcomes Trial has been published online in SPINE, the journal of the North American Spine Society.

The article, “One Year Outcomes from a Prospective Multicenter Investigation Device Trial of a Novel Conformal Mesh Interbody Fusion Device,” focuses on trial outcomes of patients treated with the OptiMesh Expandable Interbody Fusion System.

The unique OptiMesh device expands in three dimensions, enabling surgeons to perform interbody fusion procedures through an access smaller than any other fusion procedure. Print publication is anticipated before the end of 2020.

SCOUT was a prospective, multicenter investigational device clinical trial. It demonstrated strong outcomes for the OptiMesh implant at one year, including:

  • Significant reduction in back and leg pain1
  • Substantial improvement in functional status that occurred early and was sustained through 12 months1
  • 90 percent “excellent” or “good” patient satisfaction scores1
  • A 98 percent fusion rate1
  • An excellent safety record with no serious, device-related, adverse events1

“We have found this innovative, minimally invasive device to be a safe and effective option for lumbar interbody fusion procedures,” said SCOUT lead investigator John Chi, M.D., M.P.H. Dr. Chi is the Director of Neurosurgical Oncology at Brigham and Women’s Hospital in Boston, Massachusetts, and Associate Professor of Neurosurgery at Harvard Medical School, and the author of the SPINE article. “The outcomes, including high fusion rates, improved function, reduced pain and high satisfaction rates, are very favorable. Additionally, the minimal exposure requirements yielded an exceptional safety profile.”

“Spineology recently received an FDA De Novo Grant for the interbody placement of OptiMesh and is preparing for a Q1 2021 launch,” said John Booth, Spineology’s CEO. “Publication of the SCOUT data is further testimony to the strength of the study. The results demonstrated by OptiMesh along with the experiences of our investigators will help take surgery for low back and leg pain to the next level by providing excellent patient outcomes, enhanced recovery and exceptional efficiency.”

In addition to the SPINE publication, the International Journal of Spine Surgery (IJSS) accepted three manuscripts discussing Spineology’s proprietary mesh technology:


1 Lu Y, Huang K, Lavoie S, Krag M, Nunley P, Bydon M. Preliminary 24-month Outcomes of a Prospective Investigation of a Novel Mesh Interbody Spacer in Single-Level Fusions. Society for Minimally Invasive Spine Surgery (SMISS) Annual Forum 2019. Las Vegas, NV. 2019 Oct 31 – Nov 2.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy